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2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is the most potent member of a class of chlorinated
hydrocarbons that interact with the aryl hydrocarbon receptor (AhR). TCDD and dioxinlike
compounds are environmentally and biologically stable and as a result, human exposure is chronic
and widespread. Studies of highly exposed human populations show that dioxins produce
developmental effects, chloracne, and an increase in all cancers and suggest that they may also
alter immune and endocrine function. In contrast, the health effects of low-level environmental
exposure have not been established. Experimental animal models can enhance the
understanding of the effects of low-level dioxin exposure, particularly when there is evidence that
humans respond similarly to the animal models. Although there are species differences in
pharmacokinetics, experimental animal models demonstrate AhR-dependent health effects that
are similar to those found in exposed human populations. Comparisons of biochemical changes
show that humans and animal models have similar degrees of sensitivity to dioxin-induced
effects. The information gained from animal models is important for developing mechanistic
models of dioxin toxicity and critical for assessing the risks to human populations under different
circumstances of exposure. Environ Health Perspect 106(Suppl 2):761-775 (1998).
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Introduction
Dioxins are a class of highly toxic and
broadly dispersed environmental contami-
nants that may pose a significant risk to
human health. Dioxins include 75 poly-
chlorinated dibenzodioxins (PCDDs), 135
polychlorinated dibenzofurans (PCDFs),
and nine coplanar and mono-ortho-substi-
tuted polychlorinated biphenyls (PCBs)
that are structurally similar to PCDDs and
PCDFs (1,2). The most potent member of
this family is 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD), which also has the great-
est affinity for the aryl hydrocarbon
receptor (AhR). For simplicity, the term
dioxin will be used to refer to any ofthese
compounds that act as AhR ligands and
elicit dioxinlike effects.
Dioxins are the unintentional contami-
nants ofmany processes involving organic
materials and chlorine. Combustion, incin-
eration, synthesis ofphenoxy herbicides
and wood preservatives, and industrial and
municipal processes such as paper manu-
facturing are the principal sources ofdiox-
ins (3). Most dioxins are resistant to
environmental and biologic degradation
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and once formed, disperse throughout the
atmosphere, soil, and water (3). Although
environmental concentrations of dioxins
are generally low, they bioaccumulate
in human foodstuffs because of their
lipophilicity and stability.
Human exposures are lifelong and uni-
versal and usually consist ofa mixture of
dioxins. Approximately 80% of human
environmental exposure to dioxins comes
from the consumption of fat-containing
foods such as milk, meat, and fish (4,5).
Although dioxins can be detected in water,
soil, and dust, these sources contribute rel-
atively little to human exposure (6).
Total exposure to mixtures of dioxins
can be assessed by calculating the total
toxic equivalent (TEQ). A toxic equiva-
lency factor (TEF) is assigned to each
dioxin based on its potency compared to
TCDD. The TEQ is the sum of magni-
tude of exposure for each constituent
dioxin multiplied by its respective TEF
(7,8). The use of the TEQ is appropriate
for PCDDs and PCDFs where TCDD
alone or a mixture with an equivalent TEQ
produce similar biologic effects (9).
Humans metabolize dioxins slowly, as
evidenced by the estimated TCDD half-
life of 5.8 to 14.1 years (10,11). Many
PCDFs have somewhat shorterhalf-lives of
2 to 4 years (12), whereas 2,3,4,7,8-pen-
tachlorodibenzofuran (PeCDF) has an esti-
mated half-life of 19.7 years in humans
(13). The limited capacity for the metabo-
lism ofdioxins results in accumulation in
the body, particularly in adipose tissue.
Residents of the United States have an
average concentration of approximately
5 ppt TCDD in their adipose tissue (14).
Because all humans contain dioxins in
their bodies, background exposures may
result in disease even if the incidence is
low. It is expected that humans will differ
in their susceptibility to the health effects
produced by dioxins. Factors such as gen-
der, developmental stage, and the effect of
Phase I and II enzyme polymorphisms are
likely to contribute to the variation in
susceptibility. Therefore, investigative
approaches that promote a better under-
standing oflow-level human responses and
variability are needed.
AnimalModels
Animal models for dioxin response can be
used to establish causation, study the
underlying mechanisms of action, aid in
developing biomarkers of risk in human
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populations, and improve the science base
for quantitative risk assessment. Integration
ofall available information describing the
toxicokinetics, biochemistry, and health
effects ofdioxins in both human studies
and animal models can be used to develop
mechanistic models for risk assessment
(15,16). The conceptual framework for
considering human and animal data forms
a parallelogram (Figure 1). This approach
can be used to infer human responses by
comparing human and animal in vitro data
with animal in vivo effects. The relation-
ship between responses in surrogate and
target tissue can be similarly inferred
through the use ofan animal model. A use-
ful animal model ofhuman response to
dioxins requires consideration ofthe char-
acteristics ofhuman exposure, the use of
comparable dosimetry to describe expo-
sure, establishing similarity in biologic
responses, and demonstrating that the
observed biologic responses are produced
by similar biochemical mechanisms.
Criteria for establishing such a model may
be summarized as follows:
* Human exposure: Known levels of
human exposures should define the
relevant ranges ofexposure for animal
models.
* Comparable dosimetry: Because ofdif-
ferent pharmacokinetics, the relation-
ship between administered dose and
internal dose may differ by species.
Responses observed in different species
should be compared using dose metrics
that correspond to the biologically
effective dose.
* Similar biologic responses: The animal
model should display health effects or
biologic responses that are similar to
those observed in human populations.
* Similar mechanisms for biochemical
effects: The relevance ofcomplex phe-
nomenaobserved in animal models, such
as changes in cellular proliferation,
Human health effects Humantissue effects
in vivo in vitro
targettissue surrogate tissue
Animal models Animal models
ofhealth effects ofhealth effects
in vivo in vitro
targettissue surrogate tissue
Figure 1. Aconceptual model forintegrating animal and
human health effects. Adapted from Clark etal. (74).
depends on asimilarity in theunderlying
mechanisms.
Human Exposure
The doses used in animal models should be
based on realistic levels ofhuman exposure
and the internal doses produced by those
exposures. Human exposure is assessed by
measuring the concentrations ofdioxins in
the lipid fraction of the blood. Environ-
mental sources, induding dietary exposure,
give rise to detectable serum levels ofdiox-
ins in virtually all individuals (4,6). Adults
typically have total dioxin levels of 36 to
58 ppt TEQ (17) (Table 1). Ofthis total,
the coplanar and mono-ortho-substituted
dioxinlike PCBs contribute from 8 to 17
pptTEQ (17).
There is considerable variation in normal
human exposure to dioxins. Dietary prac-
tices, such as the consumption of food-
stuffs that bioaccumulate dioxins, can
significantly contribute to exposure in
adults. Heavy consumption of crabs by
Norwegian fishermen results in blood
levels of PCDDs and PCDFs that exceed
the levels in nonconsumers by 5-fold (18).
Breast-fed infants may be exposed when
lipophilic dioxins are excreted in breast
milk. This is supported byverylimited data
that show slightly higher tissue levels in
infants that are breast-fed rather than for-
mula-fed (19). Based on analysis ofbreast
milk, infants have a daily exposure of
approximately 70 pg TEQ/kg/day, which
exceeds average adult daily exposures by an
order ofmagnitude (20).
Several human populations have been
highly exposed because of accidental
releases, employment in the chemical
industry, and gross contamination offood-
stuffs. Studies of these populations have
proved invaluable for understanding the
occurrence ofdioxin-induced health effects
in humans. Lipid-adjusted serum levels
exceeding 500 ppt have been measured in
some members of these populations
decades after cessation ofhigh exposure.
Accounting for the passing ofseveral half-
lives, many individuals have had serum
lipid dioxin levels in excess of 1000 ppt.
Comparable Dosimetry
Qualitative differences in exposure estimates
can arise because humans are exposed to a
mixture of dioxins whereas most animal
models use only a single compound.
Accordingly, human exposure in human-
animal model comparisons should be
expressed as the total TEQrather than the
single compound used in the animal
model. This is most important with low-
level environmental exposures where
TCDD usually makes up only 20 to 33%
of the total TEQ (21). Under these cir-
cumstances, comparisons based on TCDD
values rather than the total TEQ will over-
estimate the impact ofTCDD. Estimating
the total TEQis less critical in situations if
thepopulation washighlyexposed to a sin-
gle dioxin as with the TCDD release in
Seveso, Italy.
Several alternative dose metrics can be
used forquantitative comparisons ofdioxin
response between species. Among them are
intake, tissue concentration, body burden,
and total cumulative dose expressed as area
under the curve (AUC).
Intake ofdioxins is usually expressed
as average daily dose (picograms/kilo-
grams/day). Intake is the most convenient
method ofmeasuring exposures in animal
models. In humans, average daily dose can
be estimated by measuring levels in food-
stuffs and monitoring consumption. In
contrast, estimation ofdaily dose stemming
Table 1. Dioxin exposure of selected human populations based on contemporary lipid-adjusted serum levels.
Population Exposure source TEQ, ppt lipid Reference
U.S. adults Background 28-41a DeVito etal. (17)
Environmental 8-17b
Norwegian malesc Seafood (crab) consumption 1loa Johansen etal. (18)
Infants Breast milkd 3.4a(adipose) Beck etal. (19)
Infantformulae 2.8, 2.1a(adipose)
Chemical industry workers, Occupational, accidental <1-5539 Ott etal. (183)
BASFcohortf
Chemical industryworkers, Occupational, 1952-1984 29-500a Flesch-Janys et al. (13)
Boehringer cohorth
Residents ofSeveso, Italy, Accidental, 1976 1-909 landi etal. (181)
Seveso cohorti
FTEQ based on PCDDs and PCDFs. hTEQ based on coplanarand mono-ortho-substituted PCBs. On=9. dn=1. In=2.
fn=138. UTCDD only. hn=45. in=103.
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from episodes ofhigh or changing dioxin
exposure is not straightforward. The daily
intake for highly exposed human popula-
tions is usually based on current serum
dioxin levels and time elapsed since the
exposure. This value has a high degree of
uncertainty because ofthe length oftime
since last exposure, heterogeneity ofdioxin
half-life in humans, and changes in daily
exposures over time.
Tissue concentrations, body burden,
and AUC more closely estimate individual
internal dose than expressions ofexposure
such as intake. As such, estimates can
reflect the impact ofintra- and interspecies
differences in half-life for TCDD, which
varies from 15 days in the mouse (9) to
as long as 14.1 years in humans (10,11)
(Table 2). Metrics ofinternal dose can also
incorporate the impact ofphysiologic fac-
tors. For instance, aging increases the body
burden of dioxins in both rodents and
humans (14,22). For comparison, the con-
centration ofdioxins residing within the
lipid fraction are estimated and reported.
The adjustment for lipids is based on the
assumptions that dioxins reside solely
within the lipid compartment and that the
dioxin concentration in lipid is uniform
throughout the body.
Dioxin exposures expressed as body
burdens are based on measurements oflipid
dioxin levels corrected for the proportion of
the body mass consisting oflipid, usually
22% in humans (17). AUC is a dose metric
that estimates the total cumulative internal
dose by integrating dose magnitude with its
duration. Differences in life expectancies
limit the use ofAUC for interspecies com-
parisons because ofuncertainties in scaling
exposure duration. Also, past episodes of
exposure, such as those encountered in
highly exposed human populations, may be
difficult to reconstruct ifonlycontemporary
dioxinvalues areavailable.
Carcinogenic doses can be used to
compare alternative dose metrics in rats,
mice, and humans, as shown in Table 2.
The average daily dose associated with
cancer is greater in mice than in rats, sug-
gesting a possible difference in sensitivity.
A meaningful average daily intake is diffi-
cult to estimate for the human population
because human high-level exposures took
place between 1952 and 1984 (13) and
were followed by several years oflow-level
environmental exposures.
There are limitations in the use of
tissue-specific comparisons between rodents
and humans due to the dose-dependent
sequestration ofdioxins in the rodent liver.
Typically, the TCDD concentration in
rodent liver tissue ranges from 1 to 10.5
times the concentration in adipose tissue,
depending on the dosing regimen (23,24).
Because ofthe sequestration, hepatic tissue
concentrations in the exposed rat may not
be representative of tissue levels in serum
and potential target organs such as the thy-
roid (Table 2). In humans the sequestration
of dioxins in hepatic tissue is not well
understood. With low-level environmental
Table 2. Comparison ofTCDD half-life and alternative dose metrics in rats, mice, and humans.
Humans
Sprague- Adult Adult
Dawley rat B6C3F1 mouse high exposure low exposure
TCDD half-life 12-31 days(2) 15days(9) 5.8-14.1 years(10,11)
Health effect Thyroid cancer(72) Liver cancer(72) All cancersa(185) Not known
Average daily intake, 1400 71,000 Not known 1-10TEQbc( 186)
pg/kg/day
Tissue, ppt lipid 6500(liver)d ND 545-4362ef(serum) 36-58 TEQb(serum) 17)
1250(serum)d
Body burden, ppt 73(liver)g 944(17) 120.960e. 8-13 TEQb( 17)
250(serum)h
ND, no data. aRelative risk ratio 2.7 (confidence index 1.7-4.4); significant increase (p<0.011 based on lineartrend
for exposure quintiles plus 9th and 10th deciles; exposure data shown for the most highly exposed decile. bTEQ
based on PCDDs, PCDFs, and coplanar and mono-ortho-substituted PCBs. clntake estimated from food consump-
tion and dioxin concentrations. dLiver and serum concentrations were determined by linear regression of averaged
daily dose and the corresponding tissue levels ofTCDD in 30-week-old animals treated biweekly with TCDD for 30
weeks; assumes lipid content of rat liver and serum of 4 and 0.4%, respectively (GW Lucier, unpublished observa-
tions). °TEQ based on PCDDs and PCDFs. fExtrapolated to last known exposure based on serum TCDD concentra-
tion, first order elimination kinetics, and elimination half-lives measured in Flesch-Janys et al. (13). #Calculated
using the liver concentration ofTCDD and assuming a liver:adipose ratio of 1 and that liverand adipose contribute
85% ofthe total body burden ofTCDD. hCalculated using the lipid-adjusted serum level and assuming a total body
lipid content of 20%. iBody burden calculated based on contemporary serum concentrations extrapolated to last
known exposure and an average of22% bodyfat.
exposures, similar concentrations ofTCDD
are found in the liver and adipose tissues of
humans (25,26). Cross-species compar-
isons of tissue concentrations should be
approached with caution.
Characterization of the carcinogenic
dose on the basis ofbody burdens, how-
ever, suggests that despite the large differ-
ence in intake and tissue concentrations,
similar body burdens are associated with
cancer in rats, mice, and humans (Table 2).
The comparability of the carcinogenic
doses across species suggests that rats and
mice could serve as experimental animal
models for further studies ofthe mechanism
ofresponse.
As in Table 2, the average dioxin
exposure from environmental sources
results in tissue lipid levels (36-58 ppt
TEQ) and body burdens (8-13 ppt TEQ)
that are more than 2 orders ofmagnitude
lower than the carcinogenic doses in either
highly exposed humans or rats. The human
cancer risk posed by this low-dose exposure
is unknown. The use ofexperimental ani-
mal models could assist in defining the
low-dose region by comparing the dosime-
try of dioxin-dependent biochemical
changes associated with cancer in both
humans and animals.
Biologic Responseto Dioxins
in Humans and Corresponding
Animal Models
The biologic responses attributed to dioxins
in humans and the corresponding res-
ponses found in animal models are dis-
cussed below. Because of the volume of
literature that examines the effects ofdiox-
ins in humans, a comprehensive review is
not possible. Representative studies exam-
ining comparable outcomes in human and
animal models were selected. Whenever
possible, studies that demonstrated dose
dependency and adequately controlled
covariates were chosen. The principal
dioxin-induced biologic responses occur-
ring in both humans and experimental
animal models indude the following:
* Chloracne
* Altered sex hormone levels
* Altered developmental outcomes
* Altered thyroid function
* Altered immune function
* Cancer
* Presence and functionality oftheAhR
* Phase I and Phase II enzyme induction
* Altered epidermal growth factor recep-
torsignaling
* Altered cellular growth and differentia-
tion
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AcuteandHigh-DoseEfflts
Dioxins produce a syndrome of toxicity,
characterized by progressive weight loss
and delayed lethality, in rats, mice, rabbits,
guinea pigs, hamsters, and nonhuman
primates (27). Acute toxicity has not been
observed among highly exposed humans
despite the occurrence ofhigh accidental
exposures that exceed the doses known to
produce acute toxicity in guinea pigs (28).
The elicitation ofthe acute toxicity syn-
drome in rhesus macaques by PeCDF (29)
suggests that whereas humans are tolerant,
similar effects would be possible with
sufficient exposure.
Chloracne is a reversible but often
disfiguring skin condition characterized by
acneiform eruptions due to epidermal
hyperkeratosis and hyperplasia (30). High
exposures, where plasma levels exceed 100
ppt lipid, may produce chloracne in many,
but not all, individuals (31,32). Indi-
viduals who consumed up to 1 g ofPCDFs
and PCBs in contaminated rice oil devel-
oped chloracne and dermatologic and
metabolic disorders that are collectively
referred to as Yu-cheng (33). Animal
species known to develop chloracnelike
lesions include rhesus macaques, rabbits,
and rodents (17,27,29). In experimental
animal models such as the rhesus macaque,
the chloracnelike lesions may be accom-
panied by epidermal changes affecting the
toenails and sebaceous glands (29). Similar
changes have been observed in human
children exposed prenatally to high
concentrations ofPCDFs and PCBs (34).
Reproductive, Developmental,
andImmunologicEff&ts
Exposure to dioxins has been linked to
alterations in endocrine and possibly repro-
ductive capabilities in humans. In a popu-
lation ofhighly exposed chemical plant
workers, plasma levels ofluteinizing hor-
mone and follicle stimulating hormone
were positively correlated to blood lipid
dioxins that ranged from below 20 to 3400
ppt. There was also a trend for reduced
testosterone in these workers (35).
Few studies have examined reproductive
outcome as a function ofdioxin exposure
in human populations. Indirect evidence
that alterations in endocrine status may
affect reproduction comes from a study of
the gender ratio ofchildren born to parents
exposed by the accidental release ofTCDD
in Seveso. During the 7 years following the
release, the proportion offemale children
was significantly elevated (48 females
compared to 26 males) (36).
In male rats, exposure to TCDD
produces testicular abnormalities and
reduces plasma testosterone levels (37).
Developmental exposure to TCDD in the
male rat results in subsequent impairment
ofreproductive capabilities (38).
Early exposure to toxicants can produce
developmental effects in the form ofphysi-
cal malformations and altered growth and
maturation. Some developmental effects,
such as physical malformations, may be
detectable at birth whereas others, such as
changes in growth, can be manifested at any
time until the onset ofsexual maturity (39).
The children ofTaiwanese women with
Yu-cheng were exposed to high concen-
trations of PCBs and PCDFs transplacen-
tally and in some instances through breast
milk. At ages 6 to 7 they exhibited disor-
dered behavior, increased activity (40), and
impaired cognitive development (41).
A Dutch study examined the effect of
the dioxins in normal breast milk by com-
paring breast-fed and formula-fed infants
(42). Standardized tests ofmental and psy-
chomotor development suggested a transi-
tory reduction in psychomotor skills in the
breast-fed infants that was related to their
intake of contaminants. Even so, as a
group, breast-fed infants performed better
than formula-fed infants (42). The children
were also exposed to nondioxinlike PCBs,
which other investigators have found to be
related to reductions in psychomotor func-
tion (43). The effect ofthe nondioxinlike
PCBs was correlated with transplacental
rather than perinatal exposure (43).
Dioxins in breast milk may also alter
the level of thyroid hormones in human
infants. Highly exposed infants had ele-
vated thyroid stimulating hormone (TSH)
levels and lower free thyroxine (T4) levels
than less-exposed infants. In all cases hor-
mone levels were within normal clinical
ranges (44).
Experimental animal models support
the putative developmental effects seen in
humans. Exposure to dioxins adversely
affected learning in young rhesus macaques
(45), whereas toxic levels of the dioxin
PeCDF reduced the level ofcirculating T4
and increased TSH levels in adult rhesus
macaques (29). A similar pattern ofaltered
plasma thyroid hormone was produced by
TCDD in rats (46). Exposure ofrodents
to dioxins either in utero or neonatally via
maternal milk reduced body weight,
delayed development, and caused immuno-
logic disturbances (47,48). Dioxins are
potent murine teratogens that produce
hydronephrosis and cleft palates at doses
below those producing maternal toxicity
(23,49). In the Long-Evans rat, maternal
exposure to low levels ofTCDD results in
urogenital tract abnormalities in both
males and females and altered reproductive
behavior in the adult male (50).
Endometriosis, a disorder with both
endocrine and immunologic features, is
foundonly in femaleprimates and is charac-
terized as the nonmalignant proliferation of
the endometrial tissue outside the uterus.
An estimated 20 to 40% ofwomen have
endometriosis, which can produce chronic
abdominal pain and reduce fertility (51).
The development of endometriosis in
female rhesus macaques treated with
TCDD led to the hypothesis that dioxins
may cause endometriosis in humans (52).
Furthermore, individuals exposed by the
Seveso accident were estimated to have total
cumulative TCDD exposures exceeding the
exposure of the affected female rhesus
macaques (53). The effect ofdioxins on
endometriotic tissue has beeninvestigated in
a murine model in which endometriosis can
be surgically implanted (54). Dioxins,
defined by their cytochrome P450 lAI
(CYPlA1) enzyme-inducing activity,
enhanced the growth of endometriotic
lesions, whereas compounds lacking such
activity failed to stimulate the growth of
lesions (55). The occurrence ofendometrio-
sis in dioxin-exposed human populations is
currentlyunderinvestigation.
Immunotoxicologic investigations in
humans often evaluate the peripheral
immune system rather than host immunity
or immunodeficiency. Most approaches
either enumerate the constituents of the
circulating immune system or assess the
function ofcellular components in vitro.
Dioxin exposure has been linked with
changes in the number and function of
lymphocytes. A dose-dependent increase in
the number ofperipheral helperTlympho-
cytes was found in industrial workers with
25 to 522 ppt TEQ in their blood lipids
(56). In a group of 11 industrially exposed
individuals, dioxin exposure was correlated
with altered lymphocyte function (57).
The proliferative response to interleukin-2
and allogeneic lymphocytes from human
lymphocyte antigen-unrelated individuals
and the ability to stimulate the prolifera-
tion ofpooled allogeneic lymphocytes was
reduced (57). The functional changes sug-
gest that dioxin exposure may have either
impaired helper T lymphocyte function or
enhanced suppressor function without
altering the proportion ofT lymphocyte
subpopulations (57).
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Studies of early human development
suggest that low-level environmental expo-
sure may also produce changes in the
immune system. Prenatal exposure in
human infants was estimated from mater-
nal and infant plasma concentrations of
planar, mono-, and di-ortho-substituted
PCBs and PCDDs/PCDFs. Higher levels
ofexposure corresponded with fewer circu-
lating T lymphocyte receptor subpopula-
tions, monocytes, and granulocytes at birth
and at 3 months. Prenatal exposure was
also positively correlated with increased
numbers ofcytotoxic T cells at 18 months
ofage (58). Immune function in children
aged 6 to 10 years exposed during the
Seveso accident showed no clinical evi-
dence of immune abnormalities based on
serum immunoglobulin concentrations and
responses to T- and B-cell mitogens (59).
Subsequent to the TCDD release, 20 of
the 44 children developed chloracne,
which demonstrates that as a group their
exposure to TCDD was considerable (59).
In murine models, dioxins suppress
antibody responses and to a lesser extent T
lymphocyte responses. Low-dose exposure
to dioxins decreased the frequency ofmem-
ory T helper lymphocytes and suppressed
both T-dependent and T-independent anti-
body responses (60,61). Dioxins may also
affect nonspecific immunity by augmenting
inflammatory responses (62). Rodent
studies show that dioxins impair immune
function and, as a consequence, resistance
to viral and parasitic infections is reduced
(63,64). Dioxins produce involution ofthe
thymus at doses that exceed those required
to alter immune function (62).
Cancer
Below is a summary ofstudies performed
in highly exposed human populations that
have the greatest risk ofdeveloping dioxin-
induced cancer. The 1997 International
Agency for Research on Cancer assessment
ofthe carcinogenicity ofTCDD (6) con-
tains a comprehensive review of the evi-
dence for the carcinogenicity of PCDDs
and PCDFs in human populations.
In 1976, an accidental release ofTCDD
from a trichlorophenol manufacturing facil-
ity contaminated the countryside surround-
ing the town of Seveso, exposing
approximately 38,000 people. Rather than
estimating individual exposures, zones of
exposure were defined according to TCDD
levels measured in neighboring soils. These
estimates, which roughly corresponded to
serum lipid TCDD levels (28), were used
for a series ofepidemiologic studies that
examined cancer mortality and morbidity
in the years following the release (65-67).
The outcomes observed in the Seveso
population are particularly informative
because in contrast to the occupational
cohorts, substantial numbers offemales and
children were exposed.
Up to 15 years after the release, neither
the incidence ofcancer mortality nor mor-
bidity in the zone with the highest level of
contamination was elevated (65-67). This
seemingly contradictory finding is not sur-
prising because the expected numbers of
many rare cancers are less than one in the
subpopulation ofapproximately 800 indi-
viduals (67). In the zone with intermediate
contamination and a population numbering
approximately 6000, an excess ofhemato-
poietic cancers, including leukemia and
Hodgkin's lymphoma was found among
males living 15 years after the incident (67).
Females from this zone also showed an
increased risk ofHodgkin's lymphoma and
multiple myeloma (67). A statistically sig-
nificant increase in the incidence ofhepato-
biliaryand extrahepatic cancers was detected
among females 10 years after the accident
(66), although mortality from hepatobiliary
cancers in females was not elevated after 15
years (67). At 10 years, an increased inci-
dence ofbrain cancer was observed among
women living in the zone with the lowest
contamination (66).
The highest human exposures to dioxins
are found within industrial populations
involved in the manufacture of phenoxy
herbicides and chlorophenols. Many indi-
viduals involved in manufacturing have
blood dioxin levels that exceed background
levels by more than an order ofmagnitude
years after termination of exposure. In
most studies exposure was based on work
history rather than quantitative measure-
ment ofserum levels, making it difficult to
attribute the outcomes to dioxins. Employ-
ment, hence exposure, often lasted for
decades. However, assessment ofthe risk to
these cohorts is complicated by the pres-
ence of numerous other chemical expo-
sures. In addition most ofthe industrially
exposed populations are predominantly, if
not entirely, male.
A meta-analysis of selected cohorts
showed excess mortality from cancers for all
sites combined, lung cancer, and non-
Hodgkin's lymphoma, and weak evidence
for an elevation in soft-tissue sarcoma and
gastrointestinal cancers. (6). The associa-
tion ofTCDD with an increase in all can-
cers was further strengthened by the dose
dependence ofthe risk (13,68). In addition
a nested case-control study showed that
the odds ratio for non-Hodgkin's lym-
phoma and soft-tissue sarcoma was depen-
dent on the magnitude of the estimated
exposure (69).
Animal models support the carcino-
genic activity ofTCDD based on studies of
Syrian golden hamsters, rats, and mice
(70). Cancers observed in human popula-
tions, such as non-Hodgkin's lymphoma,
gastrointestinal cancers, and soft-tissue sar-
comas, are not replicated in the animal
models. However, comparison ofthe exper-
imental animal models shows that specific
cancers may be species, strain, or gender
specific. In both Sprague-Dawley and
Osborne-Mendel rats, female but not male
rats develop liver cancer (71,72), whereas
thyroid cancers are found in excess only
among male Osborne-Mendel rats (72).
TCDD-treated female Osborne-Mendel
rats and Swiss Webster mice develop sub-
cutaneous fibrosarcomas (72). TCDD
induces tongue, nasal turbinate, hard
palate, lung, and adrenal cancers in both
male and female rats. Both male and
female B6C3F1 mice develop lymphoma
and liver cancers, whereas thyroid cancers
are only found in females (70). Only
Syrian golden hamsters develop squamous
carcinomas ofthe facial skin (70).
Biochemical Effects
of Dioxins in Humans
and Animal Models
Estimates ofthe riskposed by dioxinswould
be enhanced by a better understanding of
the mechanisms ofeffect, characterization of
low dose response, and a more thorough
understanding ofthe range ofsusceptibility
in human populations. The previous section
demonstrates that a variety of human
responses have been linked with dioxin
exposure although the noncancer effects are
usually small with uncertain health sig-
nificance. Both the cancer and noncancer
effects may be difficult to attribute to diox-
ins because ofthe presence ofother chemi-
cals such as nondioxinlike PCBs. The
dioxin-related effects seen in experimental
animal models are consistent with those
observed in humans and further indicate
the possibility ofadverse developmental,
reproductive, and other health outcomes.
The health effects induced by dioxins
are the ultimate outcome of a receptor-
mediated process characterized by diverse
responses that include the induction of
enzymes, changes in growth factors and hor-
mones, and alterations in cellular prolifera-
tion and differentiation. The contribution
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ofexperimental animal models lies in the
ability to examine responses to dioxin in
both the intact animal and within the
affected tissues to better understand the
mechanism. Furthermore, animal models
permit the examination of the effects of
precisely measured concentrations ofspe-
cific dioxins in both the whole animal and
the target organ. This can be accomplished
without the many competing exposures
found in human populations. Most impor-
tant, responses can also be examined in tis-
sues such as peripheral blood lymphocytes,
which permits direct comparisons with
human response.
We are currently studying the effect of
dioxins onhuman health byintegratingdata
obtained from experimental animal models
with results obtained from human tissues
with either environmental or in vitro expo-
sure. A Sprague-Dawley rat tumor-promo-
tion model has been used to study the
dose-response characteristics of dioxin-
related responses (73). Initiation is accom-
plished by the administration ofa single
dose ofdiethylnitrosamine followed by mul-
tiple doses ofTCDD, usually at biweekly
intervals for 30 to 60 weeks. Murine models
include the sensitive C57BL/6J mice with
the high affinity form ofthe AhR (74) and
strains ofmice congenic for theAhR (75).
In conjunction with the animal studies,
parallel investigations ofthe biochemical
effects ofdioxin exposure are being exam-
ined in several human populations with
different patterns and levels ofexposure.
The populations include women who con-
sumed PCDF- and PCB-contaminated rice
oil (Yu-cheng) (76), people who were liv-
ing near Seveso at the time ofthe acciden-
tal release ofTCDD in 1976 (28,59,77),
workers employed in the manufacture. of
phenoxy herbicides (31) at a Boehringer-
Ingelheim chemical plant in Germany, and
volunteers with the low but detectable
exposures typical of all residents of the
United States (78,79). The range ofserum
concentrations found in the highly exposed
cohorts and their controls are listed in
Table 1.
Human biochemical response, byneces-
sity, must be characterized in an easily
obtainable and renewable tissue. Peripheral
blood, especially lymphocytes and to a
lesser extent placental tissue, have proved
invaluable for this work. Human blood
samples can be readily obtained and the
lymphocytes assayed for gene expression,
enzyme activity, and protein concentration
ofdioxin-responsive end points. Growth
factors, hormones, and dioxin congener
concentrations can be measured in the
plasma. Lymphocytes are also amenable to
in vitro manipulations. This enables the
treatment oflymphocytes with known con-
centrations ofdioxins and permits in vitro
culture where the capacity to respond to
dioxin can be assessed. The degree to which
lymphocytes reflect the dose-response char-
acteristics ofother tissues poses a potential
limitation in their use. Also, biochemical
responses, such as the expression of
cytochrome P450 1A2 (CYP1A2) may not
be detectable in lymphocytes.
ArylHydro bonReceptor
andAryl H bon Receptor
NudearTranslocator
Several lines ofevidence indicate that most
ifnot all ofthe biologic responses elicited
by dioxins are mediated by a cellular pro-
tein termed AhR to which TCDD binds
specifically and with high affinity. TheAhR
normally exists as a multiprotein cytosolic
complex consisting of the AhR ligand-
binding subunit, heat shock proteins, and
possibly other proteins [reviewed by Okey
et al. (80)]. Upon ligand binding the AhR
complex dissociates, moves to the nucleus,
and interacts with the AhR nuclear trans-
locator (ARNT). The AhR:ARNT hetero-
dimer binds to specificresponse elements on
DNA and functions as a ligand-activated
transcription factor (81,82). The more
limited studies with the human AhR indi-
cate a similar conservation ofligand and
DNA-binding function in animals and
humans (80,83). Studies in animal models
and human and animal cell systems that
evaluate the structure-activity relationships
for the various dioxins have shown a posi-
tive correlation between AhR binding
affinity and the induction ofaryl hydro-
carbon hydroxylase (CYPlAI) activity,
lethality, thymic atrophy, weight loss, and
immunotoxicity (27,80).
The AhR is expressed in all tissues and
species examined thus far (80,84,87).
Although an endogenous ligand for the
AhR has not been identified, the high
degree of conservation of functional
domains across taxonomic lines suggests
that theAhR is necessary for important cel-
lular processes, particularly during develop-
ment (83). Evidence from transgenic mice
lacking a functional AhR also supports this
hypothesis (88,89).
The use ofthe resistant DBA/2J and the
sensitive C57BL/6J mouse strains have
shown that sensitivity ofresponse to dioxins
segregates with the AhR locus and is due to
receptor structure rather than quantity (90).
In AhR genetic knockout mice, TCDD
treatment fails to induce expression of
hepatic Cyplal and Cypla2 (89), and
UDP-glucuronosyltransferase (UDP-GT),
or to produce other signs ofacute toxicity
such as thymic atrophy and hepatomegaly
(88). The constitutive expression of
hepatic Cypla2 and UDP-GT is reduced
by 85 to 90%, indicating that theAhRalso
plays a role in basal gene expression of
these genes (88).
Thus, current evidence suggests that
different AhR alleles, at least in animal
models, influence sensitivity of response
without affecting the spectrum of bio-
chemical changes produced by dioxins
(90). The reduced affinity ofthe human
AhRfor TCDD (91) suggests that humans
may be somewhat less sensitive than mice
and raises thepossibilitythat as yet uniden-
tified variant AhR alleles in humans may
influence susceptibility to dioxin-mediated
adverse effects. Although human AhR
structural variants have been identified
(91,92), a relationship between a specific
AhR genotype and responsiveness to diox-
ins has not been demonstrated in human
populations. The AhR and ARNT are pre-
sent and functional in mitogen-activated
human lymphocytes and human lympho-
cyte cell lines (74,85,93-95). Further-
more, AhR and ARNT mRNA are
detectable in resting human lymphocytes
(79,85) and after mitogen stimulation
AhR and ARNT mRNA and protein
expression increases in a time-dependent
manner (79). We are currently examining
the relationship between interindividual
differences in AhR and ARNT expression
levels and dioxin responsiveness in dioxin-
exposed human populations.
The expression of genes under the
control ofthe AhR such as CYPlAl and
CYP1A2 are ideal candidates for a quan-
titative comparison ofdioxin responsiveness
across species. Safe (96) has published a
more complete review of the dioxin-
inducibleAhR-dependent genes.Although a
direct causal role for these genes in thepath-
wayofdioxin toxicityremains to be demon-
strated, the mechanistic link between dioxin
exposure and AhR-dependent gene expres-
sion makes them potentially sensitive indi-
cators of dioxin exposure, response, or
susceptibility to adverseeffects.
Cytoch meP450 lAl
The sequence ofevents leading from the
occupancy ofthe AhR to the induction of
gene expression is best characterized for the
CYPlA1 gene (81,82,97). Only limited
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evidence currently exists for this mecha-
nism in the dioxin-regulated expression of
other genes, but is assumed to occur by a
similar mechanism.
Treatment of human and murine
lymphoid tissue in vitro with TCDD
allows for the comparison of possible
species-specific dose-response characteris-
tics. Recent evidence from this laboratory
showed that the dioxin responsiveness of
human and murine lymphocytes were qual-
itatively and quantitatively similar. Human
lymphocytes cultured with mitogen and
TCDD showed increased CYPlAI
(EROD) activity at concentrations as lowas
0.5 nM in cell culture medium (74) (SA
Masten, in preparation). Spleen lympho-
cytes from C57BL/6J mice cultured simi-
larly to the human lymphocytes showed
comparable median effective concentration
values ofapproximately 1 to 2 nM (74).
Human lymphocytes, however, demon-
strated a greater capacity for CYPlAl
induction with maximal induction values
approximately 20-fold greater than the
maximal levels ofmurine lymphocytes. The
relative level of CYPlAl induction in
murinespleen was also less than human lym-
phocytes; 3- to 6-fold compared to 10- to
20-fold (74).
Although dioxins clearly induce CYPlAl
in cultured human cells, the effect ofenvi-
ronmental or occupational dioxin exposure
on CYPlAl expression in human tissues
remains relatively unexamined. Other
CYPlAl inducers such as cigarette smoke
are associated with elevated CYPlAI levels
in tissues that are relevant for assessing
dioxin toxicity including placenta (98),
lymphocytes (99), and lung (100).
Women suffering from Yu-cheng had
elevated levels ofplacental CYPlAl activity
4 years after consumption of PCDF and
PCB-contaminated rice oils (101). Placental
TEQ levels in these women averaged
approximately 9700 ppt lipid based pri-
marily on the presence of PeCDF and
1,2,3,4,7,8-HexaCDF (102), which
accounted for >95% ofthe TEQ. CYPlA1
activity ranged from nondetectable to 64
pmol/min/mg protein in placentas from the
exposed women while the placentas from
unexposed women had no detectable
CYPIAI activity (103). CYPIAI activity
did not correlate with placental PCDF or
PCB concentration, possiblybecause ofindi-
vidual differences in response and unknown
agonist/antagonist activityofPCBs.
CYPlAI enzyme activity cannot be
detected in resting human lymphocytes but
is detectable in lymphocytes that have been
incubated with mitogens and TCDD
(104). CYPlAI inducibility in human
lymphocytes varies considerably between
individuals and this variation has been
shown to have a genetic component with
approximately 10% ofthe population hav-
ing the high inducibility phenotype (105).
Following an interesting observation by
Kellermann et al. (106) showing higher
prevalence ofthe highly inducible pheno-
type in lung cancer cases compared to con-
trols, many subsequent studies have
evaluated CYPlAI inducibility in human
lymphocytes as a possible marker for sus-
ceptibility to smoking-related lung cancer,
with equivocal results (107,108).
Two genetic polymorphisms have been
identified in the CYPIA] gene; a Msp I
restriction fragment length polymorphism
in the 3' noncoding region and a single
nucleotide substitution resulting in an
amino acid change (Ile/Val) in the domain
responsible for catalytic activity. Population-
based studies have yielded conflicting
evidence for an association between these
polymorphisms and either in vitroinducibil-
ity ofCYPlAI or risk for specific types of
cancer (107). This may be accounted for by
an absence offunctional significance for the
genetic polymorphisms. Indeed, the Ile/Val
polymorphism within the CYPlA1 catalytic
domain was recently shown to have no
effect on catalytic activity (109,110). Ethnic
differences in allele frequencies may also
account for the conflicting results. The
CYPlAI Msp I variant allele associated in
some studies with high enzyme inducibility
has the greatest prevalence in Asian popula-
tions (111). In a recent meta-analysis ofsev-
eral published studies, therewas asignificant
link between the two CYPlAI genetic poly-
morphisms and cancer risk inJapanese pop-
ulations but not Caucasians or other ethnic
groups (111).
Although an association between known
CYPlAI genetic polymorphisms and
inducibility has been noted in some studies
(107), it is unlikely these polymorphisms
account for the observed range ofCYPlAI
inducibility phenotypes in the human popu-
lation. Indeed, recent genetic evidence has
shown the CYPlAI high inducibility phe-
notype segregates with the chromosomal
region containing the AhR structural gene
(112). In the context ofour current studies
in dioxin-exposed populations, we are evalu-
ating CYPlAI levels as possible biomarkers
ofexposure and susceptibility and attempt-
ing to identify factors that may explain
and/or modify the interindividual variation
in dioxin responsiveness. Preliminary
evidence suggests that the distribution of
CYPlA1 inducibility in human populations
may be associated with the magnitude
and/or pattern ofexposure. A 7-fold range
ofinducibility was obtained in lymphocytes
from 15 individuals with presumed back-
ground dioxin exposures. Lymphocytes
from 85 occupationally exposed individuals
showed a 27-fold variation in inducibility
(104), whereas those exposed in the Seveso
accident showed an 11-fold variation (113).
Further analyses that correlate individual
CYPlAl activity with exposure status will
determine the degree to which these differ-
ences correspond to either dioxin exposure
or responsiveness.
Although it is possible to measure
CYPlAl induction after in vivo dioxin
exposure in human tissues such as lympho-
cytes, the analysis ofCYPlAl expression in
animal models has been critical in character-
izing the dose response for effects ofTCDD
exposure on gene expression in vivo.
CYPlAl is inducible by TCDD and other
AhR agonists in multiple animal models
and in tissues, including liver, lung, kidney,
and small intestine (114-116). In the rat
liver, immunohistochemical analysis ofthe
dose-dependent expression ofCYPlAI pro-
tein in chronically exposed animals shows
that the number ofcells expressing CYPlAI
increases with increasing dose in a centrilob-
ular-specific pattern (73). Even at high
doses some cells are not induced, which sug-
gests that individual cells may differ in their
TCDD dose-response characteristics (73).
CYPlAI expression has been observed in
human liver and also exhibits a similar pat-
tern ofexpression (117), although it is not
known whether this pattern is related to
dioxin exposures. Induction of CYP1Al
expression in the rat liver is the most sensi-
tive response observed in vivo following
exposure to TCDD (118). Significant
increases in CYPlAI expression have been
observed at liver TCDD concentrations as
low as 64 ppt lipid (assuming a lipid con-
centration of4%), a level that is elevated
but within the range ofdioxin concentra-
tions observed in human livers (6).
While CYPIAI induction in vivo is
highly correlated with dioxin exposure in
animal models and indicative of a func-
tional AhR signal transduction pathway,
the role ofCYPlAI in the development of
adverse heath affects associated with dioxin
exposure is unknown.
CytochromeP450 1A2
CYP1A2 is the second member of the
TCDD-inducible CYPIA subfamily and,
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like CYPlA1, is induced by TCDD via an
AhR-dependent pathway and a mechanism
similar to that ofCYPlAl. In contrast to
CYPlAl, CYP1A2 expression is observed
in normal livers and inducibility by AhR
agonists is primarily localized to the liver
(114), although expression has been
detected in other tissues.
CYP1A2 expression has been observed
in the liver of humans with presumed
background environmental exposure to
dioxins (119). The levels of CYP1A2
mRNA in the liver of these individuals
varies about 20-fold and is from 2 to 30
times higher than the expression of
CYPlAl molecules (119). Whether the
variability in CYPlAl and CYP1A2 levels
is related to dioxin exposure is not known.
CYP1A2 activity can be detected in
humans indirectly by monitoring meta-
bolites in urine (120) or exhaled air (121)
after the administration ofcaffeine. CYP1A2
expression is induced in humans by inges-
tion ofomeprazole, smoking blonde tobacco
(120), and eating pan-fried meats (122).
Elevated CYP1A2 activities have also been
observed in chemical plant workers who had
serum levels as high as 147 ppt ofTCDD
(123), although these findings were not sta-
tisticallysignificant.
In rats chronically exposed to TCDD,
CYP1A2 protein is induced in the liver
approximately 10-fold, compared to 200-
fold for CYPlAl, yet the maximum level of
expression ofthe two CYPIA isozymes is
similar (73,124). Like CYPlAl, the induc-
tion of CYP1A2 with increasing liver
TCDD burden exhibits a centrilobular-spe-
cific pattern ofexpression (73). CYP1A2
expression is an important factor in compar-
ative pharmacokinetics ofTCDD between
species because it functions as a TCDD
binding protein (125), and as a result is
responsible for hepatic sequestration of
TCDD inrodents (126).
In contrast to CYPlAl, the expression
ofCYP1A2 is implicated in one mechanism
ofhepatocarcinogenesis ofTCDD in rats.
CYP1A2 is involved in the metabolism of
estrogen to catechol estrogens (127), which
may serve as a source for reactive oxygen
species and may potentially result in oxida-
tive stress and indirect genotoxicity (128).
CYP1A2 also catalyzes the N-oxidation of
arylamines (129) and has been linked to an
increase in risk for colorectal cancer (130).
Cytocom eP450 1B1
Cytochrome P450 iB1 (CYP1Bi) is the
first member ofaTCDD-inducible CYPIB
subfamily ofcytochromes P450 that has
been cloned from humans (131,132), mice
(133,134), and rats (135,136). Human
and rodent CYP1B1 proteins catalyze the
bioactivation ofa broad spectrum ofcom-
pounds including polycyclic aromatic
hydrocarbons and aromatic amines
(137-139). Truncating mutations in
human CYP1B1 are the primary cause of
congenital glaucoma in humans (140),
which suggests that CYPIBI is involved in
the metabolism ofendogenous substrates
involved in normal cell growth and differ-
entiation. Human CYPiBi is active in
the formation of the catechol estrogen
4-hydroxyestradiol (141), which is carcino-
genic in male hamsters (142). The forma-
tion of 4-hydroxyestradiol has been
implicated in the development ofhuman
mammary tumors and uterine leiomyoma
(143), and CYPiBi protein expression is
frequently observed in wide variety of
malignant tumors (144). CYP1Bi there-
fore represents a TCDD-inducible gene
that is plausibly linked in multiple mecha-
nisms ofcarcinogenesis through the forma-
tion ofpotentially genotoxic metabolites of
estrogens, the activation ofprocarcinogens,
and altered cell growth and differentiation.
CYP1Bi is normally expressed in
human fetal heart, brain, and kidney
(138) and in rat adrenal glands and testes
(135,136). Expression of CYP1BI is
inducible byTCDD in multiple human cell
lines (131,132,145) and in multiple rodent
tissues, including liver, lung, and kidney
(135). CYPIBI also exhibits a centrilobular
pattern ofexpression in TCDD-treated rat
liver (146) but is expressed at lower levels
and exhibits a TCDD dose response
different from thatofCYPlAI (147,148).
CYPIBI expression is detectable in
human lymphocytes and inducible by
TCDD in mitogen-stimulated lympho-
cytes treated with TCDD in vitro (104).
Expression of CYP1Bi is higher in
bronchial epithelial cells obtained from
smokers than from nonsmokers (149), sug-
gesting that CYPiB1 may be inducible in
vivobyAh receptor agonists present in ciga-
rette smoke. Current studies in our labora-
tory are evaluating the relationship between
prior TCDD exposure and CYPiBi
expression in lymphocytes from several
different human populations.
The following biochemical responses
include changes in differentiation and pro-
liferation ascertained either through direct
effects on target tissue such as the liver or
by alterations in growth factors or their
receptors. Unlike the cytochrome P450s,
these dioxin-induced changes are not the
result of direct transcriptional control by
the AhR, but integrate many biochemical
changes subsequent to AhR binding and
effects on gene expression.
EpidermalGrwth FactorReceptor
The epidermal growth factor receptor
(EGFR) is a transmembrane glycoprotein
with tyrosine kinase activity that mediates
the actions of the polypeptide hormones
epidermal growth factor (EGF) and trans-
forming growth factor alpha. Ligand bind-
ing results in receptor autophosphorylation
and internalization accompanied by phos-
phorylation and activation ofdownstream
effector proteins (150). The EGFR is
widely expressed and functions in cellular
growth and differentiation in multiple tis-
sues including the liver and gastrointestinal
tract (151). The EGFR also regulates the
implantation, growth, and differentiation
of the placenta (152), and alterations in
EGFR signaling pathways may be involved
in carcinogenesis (153).
EGF-stimulated autophosphorylation
of the EGFR in placentas from women
with Yu-cheng was reduced by approxi-
mately 60% compared to unexposed
controls (76). The reduction in auto-
phosphorylation ofthe EGFR was highly
correlated with the reduction in birth
weight seen in the offspring ofthe exposed
mothers, and with placental PCB, but not
PCDF, concentration. TCDD treatment
also reduces EGFR binding capacity in
human keratinocytes (154).
TCDD-mediated decreases in EGFR
binding capacity were observed in both
mice (155) and rats (156). In the rat
tumor promotion model, TCDD treat-
ment led to a dose-dependent reduction in
EGFR-stimulated autophosphorylation,
EGFR protein, and EGFR maximal bind-
ing capacity while the ligand-binding
affinity of the receptor was unaffected
(156,157). The magnitude ofthe decrease
(60%) was similar to that seen in placentas
from women with Yu-cheng. In the rat
model the reduction in EGFR binding was
correlated with increased hepatocyte label-
ing index (156), suggesting a possible rela-
tionship to tumor promotion. Both the
decrease in EGFR levels and the increased
proliferation depend on the presence of
ovarian hormones because the TCDD-
mediated changes were greater in intact
than ovariectomized female rats (156).
Despite a similar maximal magnitude
of reduction in EGFR autophosphoryla-
tion in the rat model and women with Yu-
cheng, EGFR maximal binding capacity
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was not reduced in the women with
Yu-cheng (103). This difference may be
due to a difference in the level ofexposure
because the average dioxin concentrations
in the placentas from the exposed women
was approximately 100 ppt TEQ wet
weight while the lowest liver concentration
producing changes in maximal binding
capacity in the rat model was approxi-
mately 1800 ppt TCDD wet weight
(156). On a body burden basis, however,
this effect occurred at a similar dose in rats
and humans (2158 vs 2582 ng/kg).
ThyroidFunction
TCDD causes dose-related significant
increases in thyroid follicular cell adenomas
in female B6C3F1 mice and male Osborne-
Mendel rats (70). One putative mechanism
for thyroid carcinogenesis is that decreased
concentrations ofserum thyroid hormones
leads to a negative feedback regulation on
the hypothalamic and pituitary glands,
which results in an increase in secretion of
TSH. Prolonged stimulation ofthe thyroid
gland by TSH may lead to follicular cell
hyperplasia and subsequently to tumors
(158). UDP-GT is a Phase II conjuga-
ting enzyme that glucuronidates thyroid
hormones and is active in the excretion of
a variety ofother endogenous and exoge-
nous molecules (159). UDP-GT is
inducible by TCDD in human and rat tis-
sues (160,161), and several animal studies
have shown that TCDD as well as other
compounds that increase hepatic levels of
UDP-GT lower circulating levels ofthy-
roid hormones, presumably through a
UDP-GT-mediated increase in clearance
from the body (162,163). Evidence also
exists that dioxin exposure is associated
with altered thyroid hormone status in
human populations (44,164,165).
Dioxin-related changes in the serum
levels ofT4, 3,5,3'-triiodothyronine (T3),
TSH, and UDP-GT mRNA were mea-
sured in a rat tumor promotion model
(166). TCDD treatment led to a dose-
dependent decrease in serum T4, which
correlated with liver TCDD burden and
increased UDP-GT mRNA. These
changes were accompanied by increased
serum TSH and thyroid follicular cell
hyperplasia. Significant changes in these
end points occurred at liver burdens of450
to 1800 ppt TCDD wetweight, equivalent
to a daily dose of3.5 to 10.7 ng/kg/day for
30 weeks.
The mechanisms and dosimetry under-
lying these observed biologic phenomena
were further examined by physiological
modeling of the alterations in thyroid
hormones and induction of UDP-GT
observed in the rat (167). The thyroid
hormones T3 and T4 were added to an
existing mechanistic model of TCDD
(168) by adding compartments and terms
for secretion, uptake, transport, glu-
curonidation, and deiodination. The
model incorporates the induction of
UDP-GT by TCDD via the AhR com-
plex and the subsequent increase in glu-
curonidation of T4. T4 secretion was
modeled as regulated by hypothalamic
and pituitary factors, which in turn were
based on a feedback mechanism con-
trolled by blood levels ofT4. The resul-
tant model successfully reproduced blood
T3, T4, and TSH levels in rats receiving
biweekly oral dosing. The ability of this
model to accurately represent biologic
processes is demonstrated by the correct
prediction of liver TCDD concentrations
and UDP-GT expression. Data measuring
these end points were not used to con-
struct the model, but were confirmed
experimentally (167).
CellularProliferaion
andDifferentiation
Although a direct causal relationship
between changes in cellular growth and
differentiation and adverse health effects is
not known, disruption ofcellular home-
ostasis could certainly be a risk factor for
carcinogenicity or other toxic effects.
Changes in cellular proliferation and
differentiation represent critical steps in
dioxin carcinogenicity that cannot readily
be studied in exposed human populations.
Chronic exposure to TCDD in animal
models results in a broad spectrum of
changes in cell proliferation and differenti-
ation (169,170). This likely results from
the effect ofdioxins on multiple hormone
and growth factor signal transduction
pathways that are involved in cell growth
and homeostasis. The development of
altered hepatic foci, characterized by the
expression of the enzymes y-glutamyl-
transpeptidase and placental glutathione
S-transferase (124,171), is the result of a
complex interaction between cell prolifera-
tion, apoptosis, and hepatocyte differentia-
tion. In a rat two-stage tumor promotion
model, chronic exposure to increasing
doses ofTCDD up to 125 ng/kg/day for
30 weeks results in increased cell prolifera-
tion and altered hepatic foci formation
(172,173). Both the number and size of
the foci are increased by dioxin exposure
(172), although there is considerable
interindividual variability in response that
does not correlate with either liver TCDD
concentration or with the induction of
cytochrome P450s (172). TCDD-induced
increases in cell proliferation and foci
development are dependent on the pres-
ence ofovarian hormones (124), and this
correlates with the female-specific induc-
tion of tumors in rats (71). One of the
characteristics of tumor promotion is
reversibility on cessation of treatment.
Withdrawal ofTCDD treatment leads to a
reduction in number of altered hepatic
foci; however, the focal size and percent of
liver occupied by foci increases (173-175).
These data suggest that TCDD treatment
may promote the development ofa popu-
lation offoci that may be able to continue
to develop in the absence ofTCDD.
Although the response to dioxins has
been best characterized in liver tissue, ani-
mal models show that dioxin alters prolif-
eration and differentiation in other tissues
as well. In mice, prenatal TCDD exposure
results in cleft palate due to a disruption in
proliferation and differentiation ofepithe-
lial cells required for fusion of the palatal
shelves (176). The expression ofAhR and
ARNT in human embryonic craniofacial
tissues indicates the machinery for
responding to TCDD is present (177). A
single dose of TCDD (either 2.5 or 25
pg/kg) in pubertal female Sprague-Dawley
rats reduced ovarian weight and inhibited
mammary cell development and differenti-
ation by reducing the number ofterminal
ductal structures and gland size (178).
In vitro systems allow for the study of
the effects ofTCDD on growth and prolif-
eration of human cells including primary
and immortalized keratinocytes, embryonic
craniofacial tissues, and MCF-7 breast
cancer cell line. Normal human epidermal
keratinocytes treated with 10 nM TCDD
showed an increase in markers ofterminal
differentiation while the total number of
cells remained constant (179). The estro-
gen-dependent growth ofMCF-7 cells was
inhibited by 0.3 nM TCDD (180). In
addition, several studies have shown that
TCDD can induce transformation ofboth
rodent and human cells in vitro (170).
Gender Differences inResponse
Evidence from the analysis of serum
TCDD levels in the Seveso population sug-
gests that dioxin pharmacokinetics may dif-
fer in respect to gender. Twenty years after
the initial exposure, the average serum level
in females was approximately three times
that found in males (181). This observation
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could not be accounted for bydifferences in
the initial exposure, percentage ofbody fat,
or several other covariates.
Rodent cancer bioassays indicate that
TCDD is a hepatic carcinogen in female
but not male rats (71), implying that the
presence ofestrogens influences the car-
cinogenic response. Indications that a
similar process occurs in humans comes
from the 10-year follow-up of those
exposed in the Seveso incident. Women
but not men showed an excess of liver
cancer (66). This excess was present but
not statistically significant 15 years after
the accident (67).
Rodent models suggest that the pres-
ence of ovarian hormones, presumably
estrogens, play a role in modifying many
effects ofTCDD that are correlated either
with the development ofhepatic preneo-
plastic changes or tumors. Compared to
ovariectomized rats, the livers ofintact ani-
mals treated with TCDD for 30 weeks
showed a decrease in EGF receptor (156),
a greater hepatic proliferative response
(73,124), a greater volume occupied by
putative preneoplastic lesions (124), and
increased oxidative DNA damage (182),
while the quantity of CYP1A2 was not
affected (124).
Summary
The adverse effects of dioxins are well
established based on studies ofexperimen-
tal animal models and highly exposed
human populations. From these investiga-
tions, the current view ofdioxins as potent
toxicants capable ofproducing a multitude
ofdiverse biologic effects has emerged.
Much less is known about the risk
posed to humans bylifelong low-level envi-
ronmental exposure. Better character-
ization ofdose-response relationships and
the factors associated with individual varia-
tion in susceptibility are needed to evaluate
the risk to humans from background
exposures. These questions can best be
addressed with experimental animal mod-
els, provided the response of the animal
species accurately replicates the human
response. The relevance ofa particular ani-
mal model for evaluating or predicting
human response is determined by a num-
ber of properties-factors that can be
manipulated, such as dose regimens, as well
as factors that are intrinsic to the animal
model, such as biologic response. They can
be summarized as follows:
* The reproductive, developmental,
immunologic, and carcinogenic res-
ponses to dioxins seen in humans also
occur in animal models.
* The preponderance of biochemical
effects induced by dioxins in both ani-
mals and humans are mediated by the
AhR.
* Animal dosing regimens can be varied
to examine the range of exposures
encountered in human populations.
* Dose metrics based on internal dose
(tissue dose and body burden) can be
used to compare responses across species
as these parameters take into account
species differences in dearance rates.
* The biochemical responses to dioxins
in animal models show qualitative and
quantitative similarity to those observed
in humans.
Based on reviews ofexposed humans,
the corresponding experimental animal
models, and the biochemical responses in
human and animals, biologic responses to
dioxins are qualitatively and often quanti-
tatively similar. Exposure to dioxins has
been implicated in a wide range ofhuman
health effects related to reproduction,
immune function, growth and develop-
ment, and cancer. The role ofdioxins in
producing these effects is supported bycor-
responding outcomes in animal models.
The similarity in biochemical responses
makes it possible to study the underlying
mechanisms ofdioxin toxicity relevant for
humans. Most important, animal models
make it possible to study the relationship
between simple biochemical responses and
more complex responses, such as altered
growth and differentiation, which lead to
adverse health effects. This information is
integrated with human studies to infer
responses that would not otherwise be pos-
sible, such as target tissue effects. Current
efforts are underway to characterize the
effect of susceptibility factors such as
genetics, gender, age, and the dosimetry of
dioxin-dependent biochemical changes in
human populations. Parallel studies in ani-
mal models can be used to understand how
these biochemical changes can lead to
adverse health effects.
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